Promising Clinical Progress and Strong Financial Position Support Buy Rating for Vigil Neuroscience

JMP Securities analyst Jason Butler has reiterated their bullish stance on VIGL stock, giving a Buy rating today.

Jason Butler’s rating is based on the promising clinical development progress of Vigil Neuroscience’s TREM2 programs. The company has reported favorable results for VG-3927, showing a predictive pharmacokinetic profile and significant reductions in soluble TREM2 levels, which are consistent across different patient groups and demonstrate good safety and tolerability. Additionally, Vigil’s plans to initiate a Phase 2 trial for VG-3927 in Alzheimer’s disease patients highlight its potential as a differentiated candidate due to its unique mechanism of action and ability to penetrate the blood-brain barrier.
Furthermore, the anticipated final results from the Phase 2 IGNITE trial for iluzanebart in ALSP are expected in the second quarter of 2025, with the company considering an accelerated approval pathway based on interim biomarker results. Vigil’s strong financial position, with a cash runway extending into 2026, further supports the Buy rating, as it provides the company with the necessary resources to continue its clinical development efforts.

In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $11.00 price target.